0
Clinical Investigations: COPD |

Tolerance and Physiologic Effects of Nocturnal Mask Pressure Support vs Proportional Assist Ventilation in Chronic Ventilatory Failure*

João Carlos Winck, MD, PhD; Michele Vitacca, MD; António Morais, MD; Luca Barbano, MD; Roberto Porta, MD; Armando Teixeira-Pinto, MD; Nicolino Ambrosino, MD, FCCP
Author and Funding Information

*From the Departments of Pneumology (Drs. Winck and Morais) and Biostatistics and Medical Informatics (Dr. Teixeira-Pinto), Hospital São João, Faculdade de Medicina, Universidade do Porto, Porto, Portugal; Pulmonary Division (Drs. Vitacca, Barbano, and Porta), S. Maugeri Foundation IRCCS, Gussago (BS); and Pulmonary Unit (Dr. Ambrosino), Cardio-Thoracic Department, University of Pisa, Pisa, Italy.

Correspondence to: João Carlos Winck, MD, PhD, Pneumology Department, Hospital São João, Faculdade de Medicina, Universidade do Porto, Porto, Portugal; e-mail: jwinck@hsjoao.min-saude.pt



Chest. 2004;126(2):382-388. doi:10.1378/chest.126.2.382
Text Size: A A A
Published online

Study objectives: To compare the tolerance and physiologic effects of a 5-night treatment with either nasal proportional assist ventilation (PAV) or pressure support ventilation (PSV) in patients with chronic ventilatory failure.

Design: Cross-over, randomized, controlled study.

Setting: Rehabilitation units of pneumology department.

Patients or participants: Four patients with COPD and 10 patients with restrictive thoracic diseases with chronic hypercapnia (median baseline Paco2, 55.1 mm Hg) were studied.

Interventions: In a cross-over study, nasal PAV and PSV set at the patient’s comfort were randomly applied during 5 consecutive nights (with a 2-night washout period).

Measurements and results: Continuous nocturnal pulse oximetric saturation (Spo2) and arterial blood gas results at wake-up were evaluated at baseline during spontaneous breathing and on the fifth day of ventilatory support. Dyspnea, sleep quality, adaptation, and comfort at inspiration and expiration by visual analog scale (VAS) were evaluated every day as well as a side effects score. On the fifth day, there were no significant differences in daytime Paco2 (median PAV, 53.3 mm Hg; median PSV, 50.2; p = 0.168). Mean nocturnal Spo2 improved significantly with both PAV and PSV without any significant differences between modes (baseline median, 92%; PAV median, 94.5%; PSV median, 95%). The percentage of the study night spent < 90% Spo2 (T90) was slightly but significantly higher with PAV than with PSV (median PAV T90, 4%; median PSV T90, 2%; p = 0.049). The VAS symptom score was similar at day 5 between modes; however, nasal and oral dryness were lower (p = 0.05) and alarm noise was higher (p = 0.037) with PAV.

Conclusions: After 5 days of treatment, both modes had similar tolerance, and were equally effective in reducing daytime hypercapnia and improving nocturnal saturation and symptoms. However, PAV induced less nasal and oral dryness but was associated with higher alarm noise.

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
Guidelines
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543